Casey O'Connell, MD, FACP

Title(s)Associate Professor of Clinical Medicine, Lawrence and Janice Kelly Chair in Hematology
SchoolKeck School of Medicine of Usc
Address1441 Eastlake Ave.
Health Sciences Campus
Los Angeles CA 90033
Phone+1 323 865 3950
vCardDownload vCard
    Other Positions
    Title(s)Director, Gehr Cures: Myeloid Malignancy Program of USC


    Collapse Biography 
    Collapse Awards and Honors
    The Los Angeles Business Journal 2024Top Doctors of 2024 in Oncology/Hematology
    LAC+USC Medical Center 2022Outstanding Faculty Teaching Award
    The Myelodysplastic Syndromes Foundation, Inc. 2022MDS Foundation Nobility in Science Award
    American College of Physicians2017Fellowship in the American College of Physicians (ACP)
    Keck School of Medicine 2016  - 2017Outstanding Year II Teaching Award
    Keck School of Medicine2013Master Teacher Distinction
    LAC+USC Medical Center2013Medical Staff Leadership Recognition Award
    Keck School of Medicine 2012  - 2013Outstanding Year I Teaching Award
    Keck School of Medicine2011  - 2012Best Year I System
    Los Angeles Magazine Top Doctors 2010  - 2024Top Doctors Award
    Southern California Top Doctors 2010  - 2024Top Doctors
    Keck School of Medicine 2008  - 2009Outstanding Year I Teaching Award
    Division of Hematology, USC2006  - 2007Fellow Research Award
    Division of Hematology, USC2004  - 2005Fellow Teaching Award
    USC Department of Medicine2003  - 2004Senior Resident of the Year
    USC Department of Medicine2003  - 2004Brautbar Teaching Award
    Keck School of Medicine2003Outstanding Resident Teaching Award
    George Washington University Department of Medicine2001Jorge C. Rios Award in Internal Medicine
    1999Laszlo M Tauber Scholarship
    George Washington University School of Medicine1998William Beaumont Medical Research Honor Society

    Collapse Overview 
    Collapse Overview
    Dr. Casey O’Connell is an Associate Professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine, University of Southern California (USC). She did her undergraduate work at Stanford University and completed her medical degree with distinction at the George Washington School of Medicine. She began her career as a clinical researcher at USC’s Norris Comprehensive Cancer Center in the area of cancer-related thrombosis by describing the clinical significance of incidental pulmonary embolism identified on routine cancer staging CT scans. Her original work in this area was published in the Journal of Clinical Oncology and brought this clinical entity to the attention of oncologists worldwide. Dr. O’Connell’s background in cancer-related thrombosis has generated a focused interest in Myeloproliferative Neoplasms (MPNs), which include Polycythemia Vera, Essential Thrombocytosis and Myelofibrosis. In addition to leading clinical treatment trials for patients with these malignancies, she pursues translational research seeking to discover how they induce arterial and venous thrombosis. The MPNs and Myelodysplastic syndrome (MDS) are malignant hematopoietic disorders with pleiotropic clinical manifestations. Dr. O’Connell is interested in optimizing the role of epigenetic therapy in these pre-leukemic conditions that can lead to acute myeloid leukemia.

    As director of the new GEHR CURES Myeloid Malignancy Program, Dr. O’Connell is focused on optimizing therapies and on novel ways to intervene earlier to prevent progression of these disorders. Dr. O’Connell is proudest of her accolades for patient care in Southern California and for teaching at the Keck School of Medicine.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Idiopathic erythrocytosis: A diagnostic and management challenge with emerging areas for exploration. Br J Haematol. 2024 Mar; 204(3):774-783. O'Neill C, O'Connell C. PMID: 38262687.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26. Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. PMID: 38135371.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    3. Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS-IT). Eur J Haematol. 2024 Apr; 112(4):594-600. O'Neill C, Nwachukwu N, Vergara-Lluri M, Hagiya A, O'Connell CL. PMID: 38088145.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023 01 28; 401(10373):269-280. Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R, MOMENTUM Study Investigators. PMID: 36709073.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    5. Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. Clin Cancer Res. 2022 12 15; 28(24):5306-5316. O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. PMID: 36222848; PMCID: PMC9772102.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    6. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leuk Res. 2022 08; 119:106903. Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. PMID: 35717689.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022 05 12; 139(19):2931-2941. Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. PMID: 35007321; PMCID: PMC9101248.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    8. European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. Hemasphere. 2022 Jun; 6(6):e721. Tremblay D, Srisuwananukorn A, Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall A, O'Connell CL, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. PMID: 35747843; PMCID: PMC9208865.
      View in: PubMed   Mentions: 5  
    9. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022 05 20; 40(15):1671-1680. Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. PMID: 35180010; PMCID: PMC9113204.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    10. Tranexamic Acid in the Treatment of Refractory Gastrointestinal Arteriovenous Malformation Bleeding in Left Ventricular Assist Device Patients. Circ Heart Fail. 2022 01; 15(1):e008669. Fong MW, Morningstar-Kywi N, O'Connell C, Qureshi U, Han EE. PMID: 34807724.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res. 2021 10; 109:106629. Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. PMID: 34082375.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16. O'Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. PMID: 33275319; PMCID: PMC7794180.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    13. Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection. J Med Virol. 2021 05; 93(5):2645-2653. Rosen HR, O'Connell C, Nadim MK, DeClerck B, Sheibani S, DePasquale E, Sanossian N, Blodget E, Blodget E, Angell T. PMID: 33090515; PMCID: PMC7675751.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    14. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020 09 22; 4(18):4282-4291. Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, Ganz T, Kowalski M, Brachmann CB. PMID: 32915978; PMCID: PMC7509854.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    15. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683. Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. PMID: 32285126; PMCID: PMC7414597.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCellsCTClinical Trials
    16. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020 05 07; 135(19):1696-1703. Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O'Connell C, Shammo J, Fleischman AG, Scherber RM, Mesa R, Yacoub A, Perkins C, Meckstroth S, Behlman L, Chiaramonte M, Salehi M, Ziadkhanpour K, Nguyen H, Siwoski O, Hung AK, Janania Martinez M, Nguyen J, Patel S, Kollipara R, Dave A, Randall M, Grant M, Harrison M, Fernandez Soto P, Tremblay D, Hoffman R, Moshier E, Mascarenhas J. PMID: 32107559; PMCID: PMC7205813.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    17. The TEMPI syndrome. Blood. 2020 04 09; 135(15):1199-1203. Sykes DB, O'Connell C, Schroyens W. PMID: 32108223.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    18. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol. 2020; 143(3):244-249. Piatek CI, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. PMID: 31665725.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011 Feb; 9(2):305-11. O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA. PMID: 20955348.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    20. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond. Expert Rev Hematol. 2008 Dec; 1(2):175-82. O'Connell CL, Liebman HA. PMID: 21082922.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals